Clinical significance and prognosis of MYC translocation in diffuse large B-cell lymphoma

Hematological Oncology

Volumn 29, Issue 4, 2011, Pages 185-189

  Zhang, Hong Wei ^a   Chen, Zhen Wen ^b   Li, Su Hong ^a   Bai, Wei ^a   Cheng, Niu Liang ^b   Wang, Jin Fen ^a  

^a Shanxi Province Tumor Hospital   (China)

^b SHANXI MEDICAL UNIVERSITY   (China)

Author keywords

Chinese DLBCL; Chromosome translocation; FISH; MYC gene; Survival analysis

Indexed keywords

CD20 ANTIGEN; CD3 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; INTERFERON REGULATORY FACTOR 4; MYC PROTEIN; PREDNISOLONE; PROTEIN BCL 6; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHINESE; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN LOCALIZATION;

AGED; AGED, 80 AND OVER; FEMALE; GENES, MYC; HUMANS; IMMUNOPHENOTYPING; KAPLAN-MEIER ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PROGNOSIS; TRANSLOCATION, GENETIC;

EID: 83555176437     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.991     Document Type: Article

References (20)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66.
2. Gloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK. Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 2003; 8: 541-552.
3. Stewart BW, Kleihues P (eds). In World Cancer Report. IARC Press: Lyon, 2003.
4. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008; 9: 105-116.
5. Chaganti RS, Nanjangud G, Schmidt H, et al. Recurring chromosomal abnormalities in non-Hodgkin's lymphoma: biologic and clinical significance. Semin Hematol 2000; 37: 396-411.
6. Kramer MH, Hermans J, Wijburg E, et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 1998; 92: 3152-3162.
7. Stein H, Warnke RA, Chan WC, et al. In WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues: Diffuse Large B-Cell Lymphoma, Not Otherwise Specified (4th edn), IARC:Lyon, 2008.
8. Ventura RA, Martin-Subero JI, Jones M, et al. FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embedded tissue. J Mol Diagn 2006; 8: 141-151.
9. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-282.
10. Au WY, Horsman DE, Gascoyne RD, et al. The spectrum of lymphoma with 8q24 aberrations: a clinical, pathological and cytogenetic study of 87 consecutive cases. Leuk Lymphoma 2004; 45: 519-528.
11. Tibiletti MG, Martin V, Bernasconi B, et al. BCL2, BCL6, MYC, MALT1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome. Hum Pathol 2009; 40: 645-652.
12. Niitsu N, Okamoto M, Miura I, Hirano M. Clinical significance of 8q24/c-MYC translocation in diffuse large B-cell lymphoma. Cancer Sci 2009; 100: 233-237.
13. van Imhoff GW, Boerma EJ, van der Holt B, et al. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 4135-4142.
14. Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 2006; 354: 2419-2430.
15. Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 2009; 114: 3533-3537.
16. Shiozawa E, Yamochi-Onizuka T, Takimoto M, et al. The GCB subtype of diffuse large B-cell lymphoma is less frequent in Asian countries. Leuk Res 2007; doi:10.1016/j.leukres. 2007. 03.017.
17. Choi WWL, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm improves the classification of diffuse large B-cell lymphoma into prognostically significant subgroups. United States and Canadian Academy of Pathology (USCAP), 2008 Annual Meeting, Denver Colorado, 2008; March 3: 1144-1146.
18. de Jong D, Xie W, Rosenwald A, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium). J Clin Pathol 2009; 62: 128-138.
19. Valera A, Balague O, Colomo L, et al. IG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas. Am J Surg Pathol 2010; 34: 1686-1694.
20. Taddesse-Heath L, Meloni-Ehrig A, Scheerle J, et al. Plasmablastic lymphoma with MYC translocation: evidence for a common pathway in the generation of plasmablastic features. Mod Pathol 2010; 23: 991-999.